Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Design, Synthesis, and Pharmacokinetic Evaluation of O-Carbamoyl Tizoxanide Prodrugs

Author(s): Xi He, Wenjun Hu, Fanhua Meng and Xingzhou Li*

Volume 18, Issue 1, 2022

Published on: 19 November, 2020

Page: [140 - 150] Pages: 11

DOI: 10.2174/1573406416666201120102905

Price: $65

Abstract

Background: The broad-spectrum antiparasitic drug nitazoxanide (N) has been repositioned as a broad-spectrum antiviral drug. Nitazoxanide’s in vivo antiviral activities are mainly attributed to its metabolite−tizoxanide, the deacetylation product of nitazoxanide. In reference to the pharmacokinetic profile of nitazoxanide, we proposed the hypotheses that the low plasma concentrations and the low system exposure of tizoxanide after dosing with nitazoxanide result from significant first-pass effects in the liver. It was thought that this might be due to the unstable acyloxy bond of nitazoxanide.

Objective: Tizoxanide prodrugs, with the more stable formamyl substituent attached to the hydroxyl group rather than the acetyl group of nitazoxanide, were designed with the thought that they might be more stable in plasma. It was anticipated that these prodrugs might be less affected by the first pass effect, which would improve plasma concentrations and system exposure of tizoxanide.

Method: These O-carbamoyl tizoxanide prodrugs were synthesized and evaluated in a mouse model for pharmacokinetic (PK) properties and in an in vitro model for plasma stabilities.

Results: The results indicated that the plasma concentration and the systemic exposure of tizoxanide (T) after oral administration of O-carbamoyl tizoxanide prodrugs were much greater than that produced by the equimolar dosage of nitazoxanide. It was also found that the plasma concentration and the systemic exposure of tizoxanide glucuronide (TG) were much lower than that produced by nitazoxanide.

Conclusion: Further analysis showed that the suitable plasma stability of O-carbamoyl tizoxanide prodrugs is the key factor in maximizing the plasma concentration and the systemic exposure of the active ingredient tizoxanide.

Keywords: Nitazoxanide, tizoxanide, prodrugs, plasma concentrations, first pass effect.

« Previous Next »
Graphical Abstract

[1]
Gilles, H.M.; Hoffman, P.S. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol., 2002, 18(3), 95-97.
[http://dx.doi.org/10.1016/S1471-4922(01)02205-X] [PMID: 11854075]
[2]
White, C.A. Jr Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev. Anti Infect. Ther., 2004, 2(1), 43-49.
[http://dx.doi.org/10.1586/14787210.2.1.43] [PMID: 15482170]
[3]
Rossignol, J-F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res., 2014, 110, 94-103.
[http://dx.doi.org/10.1016/j.antiviral.2014.07.014] [PMID: 25108173]
[4]
Rossignol, J-F. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J. Infect. Public Health, 2016, 9(3), 227-230.
[http://dx.doi.org/10.1016/j.jiph.2016.04.001] [PMID: 27095301]
[5]
Anderson, V.R.; Curran, M.P. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs, 2007, 67(13), 1947-1967.
[http://dx.doi.org/10.2165/00003495-200767130-00015] [PMID: 17722965]
[6]
Stockis, A.; De Bruyn, S.; Gengler, C.; Rosillon, D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int. J. Clin. Pharmacol. Ther., 2002, 40(5), 221-227.
[http://dx.doi.org/10.5414/CPP40221] [PMID: 12051574]
[7]
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-497_Alinia_BioPharmr.pdf
[8]
Adagu, I.S.; Nolder, D.; Warhurst, D.C.; Rossignol, J-F. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother., 2002, 49(1), 103-111.
[http://dx.doi.org/10.1093/jac/49.1.103] [PMID: 11751773]
[9]
Rossignol, J-F.; Stachulski, A.V. Syntheses and antibacterial activities of tizoxanide, an N-(nitrothiazolyl) salicylamide, and its O-aryl glucuronide. J. Chem. Res., 1999, 23(1), 44-45.
[http://dx.doi.org/10.1039/a806676k]
[10]
Stachulski, A.V.; Pidathala, C.; Row, E.C.; Sharma, R.; Berry, N.G.; Iqbal, M.; Bentley, J.; Allman, S.A.; Edwards, G.; Helm, A.; Hellier, J.; Korba, B.E.; Semple, J.E.; Rossignol, J.F. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. J. Med. Chem., 2011, 54(12), 4119-4132.
[http://dx.doi.org/10.1021/jm200153p] [PMID: 21553812]
[11]
Davis, M.C.; Dahl, J.E.; Carlson, R.M. Preparation of Diisocyanates of Adamantane and Diamantane. Synth. Commun., 2008, 38(8), 1153-1158.
[http://dx.doi.org/10.1080/00397910701865926]

Rights & Permissions Print Cite
Article Metrics
33
3
© 2024 Bentham Science Publishers | Privacy Policy